

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

LC-2/ad

RRID:CVCL_1373

Type: Cell Line

Proper Citation

RRID:CVCL_1373

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1373

Proper Citation: RRID:CVCL_1373

Description: Cell line LC-2/ad is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: [PMID:8291444](#), [PMID:8348978](#), [PMID:16105816](#), [PMID:20164919](#), [PMID:22313637](#), [PMID:23154560](#), [PMID:23578175](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:35839778](#), [PMID:38639832](#)

Comments: Caution: Indicated to have a EGFR p.Leu858Arg (c.2573T>G) mutation according to PubMed=16105816) but this is in contradiction of results of exome sequencing in Cosmic-CLP and DepMap., Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LC-2/ad

Synonyms: LC-2-Ad, LC-2-ad, LC-2 ad, LC2/Ad, LC2/AD, LC2AD

Cross References: BTO:BTO_0006466, CLO:CLO_0037020, CLO:CLO_0050073, EFO:EFO_0003140, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472314, cancercellines:CVCL_1373, Cell_Model_Passport:SIDM00297, ChEMBL-Cells:ChEMBL3308545, ChEMBL-Targets:ChEMBL2366260, Cosmic:907786, Cosmic:946052, Cosmic:1154602, Cosmic:1571726, Cosmic:1656903, Cosmic:1995480,

Cosmic-CLP:907786, DepMap:ACH-002157, ECACC:94072247, EGA:EGAS00001000978, GDSC:907786, GEO:GSM1670043, IARC_TP53:21470, LINCS_LDP:LCL-1667, Pharmacodb:LC2ad_831_2019, PRIDE:PXD030304, PubChem_Cell_line:CVCL_1373, RCB:RCB0440, Wikidata:Q54902124

ID: CVCL_1373

Record Creation Time: 20220427T220719+0000

Record Last Update: 20260829T234456+0000

Ratings and Alerts

No rating or validation information has been found for LC-2/ad.

No alerts have been found for LC-2/ad.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Son J, et al. (2026) Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells. Molecular oncology, 20(4), 1041.

Horie M, et al. (2024) Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment. Molecular oncology, 18(1), 21.

Wei X, et al. (2024) MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer. Cancer letters, 604, 217220.

Arbajian E, et al. (2020) Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer. Cancers, 12(8).

Gudernova I, et al. (2017) Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480. Oncotarget, 8(65), 109319.